Aplastic anemia Medical Services in China

Aplastic anemia (AA) is a rare, life-threatening hematologic disorder characterized by bone marrow failure, resulting in pancytopenia—profound deficiencies of red blood cells, white blood cells, and platelets. Unlike leukemias or myelodysplastic syndromes, AA involves immune-mediated destruction or functional suppression of hematopoietic stem and progenitor cells, leading to hypocellular or acellular bone marrow without abnormal cell infiltration or fibrosis. The primary pathogenesis centers on autoreactive T-lymphocyte activation, which targets hematopoietic stem cells via cytokine-mediated apoptosis (e.g., IFN-γ and TNF-α overexpression) and Fas/FasL pathway dysregulation. In ~75% of cases, the disease is acquired, often triggered by environmental exposures—including benzene, certain medications (e.g., chloramphenicol, sulfonamides, anticonvulsants), viral infections (e.g., hepatitis viruses, Epstein-Barr virus, parvovirus B19), or idiopathic immune dysregulation. A smaller subset (<10%) arises from inherited bone marrow failure syndromes such as Fanconi anemia, Dyskeratosis congenita, or Shwachman-Diamond syndrome, typically presenting in childhood with associated physical anomalies and cancer predisposition. Epidemiologically, AA affects approximately 2–7 new cases per million people annually worldwide, with a bimodal age distribution peaking in adolescence/early adulthood (15–25 years) and again after age 60. Incidence is notably higher in East Asia, particularly China, where rates reach up to 10–15 per million—potentially reflecting genetic susceptibility, environmental factors, or enhanced case detection. Risk factors include occupational solvent exposure, prior chemotherapy or radiation, autoimmune disorders (e.g., lupus, thyroiditis), and specific HLA haplotypes (e.g., HLA-DR2). Clinically, patients present with fatigue, pallor, dyspnea (anemia), recurrent febrile infections (neutropenia), and mucocutaneous bleeding or petechiae (thrombocytopenia). Severe AA carries high mortality without treatment: median survival is <6 months untreated, with hemorrhage and sepsis being leading causes of death. Quality of life is significantly impaired—not only due to physical symptoms but also psychological burden, treatment-related side effects (e.g., immunosuppressive therapy-induced fatigue, infection risk, or GVHD post-transplant), prolonged hospitalizations, and socioeconomic strain from lost workdays and caregiving demands. Patients often experience anxiety, depression, and social isolation, especially during prolonged recovery phases or while awaiting matched donors for hematopoietic stem cell transplantation (HSCT). Early diagnosis via peripheral blood counts, reticulocyte count, and confirmatory bone marrow biopsy (showing <25% cellularity with absence of dysplasia or infiltrative disease) is critical. Prognosis depends on disease severity (classified as non-severe, severe, or very severe AA), age, comorbidities, and treatment response. With modern therapies—including immunosuppressive therapy (IST) with antithymocyte globulin [ATG] and cyclosporine, or allogeneic HSCT—5-year overall survival exceeds 80% in younger patients receiving matched sibling donor transplants and 70–75% with IST. However, relapse, clonal evolution (to MDS or AML), and chronic complications remain key challenges requiring lifelong monitoring.

Aplastic anemia (AA) is a rare, life-threatening hematologic disorder characterized by bone marrow failure resulting in pancytopenia—profound deficiencies of erythrocytes, granulocytes, and platelets—and a markedly hypocellular bone marrow without abnormal infiltrates or fibrosis. The pathogenesis is predominantly immune-mediated in acquired cases, wherein autoreactive cytotoxic T lymphocytes target and destroy hematopoietic stem and progenitor cells (HSPCs), leading to marrow aplasia. Approximately 70–80% of cases are acquired; the remainder are inherited (constitutional), often presenting in childhood or adolescence.

Common causes of acquired aplastic anemia include idiopathic immune dysregulation (accounting for ~60–70% of acquired cases), where no external trigger is identified but clonal T-cell expansions and interferon-γ–driven apoptosis of HSPCs are consistently observed. Drug-induced AA represents a well-documented cause, with high-risk agents including chloramphenicol (dose-independent, idiosyncratic), sulfonamides, phenylbutazone, gold salts, and antithyroid drugs (e.g., methimazole, propylthiouracil). Chemotherapeutic agents such as melphalan and busulfan may induce marrow failure, though typically transient and dose-dependent—true AA is rare with these. Notably, exposure to benzene and its derivatives (e.g., styrene, toluene) is a major environmental cause; chronic occupational inhalation leads to oxidative stress, DNA adduct formation, and selective toxicity to early myeloid precursors. Ionizing radiation—whether from therapeutic radiotherapy, nuclear accidents, or repeated diagnostic exposures—can cause irreversible HSPC depletion via double-strand DNA breaks and p53-mediated apoptosis.

Infectious triggers are implicated in a subset of cases. Hepatitis viruses (particularly non-A, non-B, non-C, non-E seronegative hepatitis—often linked to HGV/GB virus C or AAV2) precede AA onset in ~5–10% of young adults, typically 2–3 months post-hepatitis. Epstein-Barr virus (EBV), cytomegalovirus (CMV), and HIV have also been associated, especially in immunocompromised hosts, though causality remains less definitive than in hepatitis-associated AA. Parvovirus B19 rarely causes transient red cell aplasia but not classic pancytopenic AA.

Genetic factors underlie inherited bone marrow failure syndromes that predispose to AA. Fanconi anemia (FA), caused by biallelic mutations in any of >23 FANC genes involved in DNA interstrand crosslink repair, presents with congenital anomalies, progressive cytopenias, and extreme sensitivity to DNA crosslinking agents (e.g., diepoxybutane). Dyskeratosis congenita (DKC), due to mutations in telomere maintenance genes (e.g., DKC1, TERC, TERT, RTEL1), manifests with mucocutaneous triad (abnormal skin pigmentation, nail dystrophy, leukoplakia), pulmonary fibrosis, and very short telomeres—conferring high risk of marrow failure and myeloid malignancy. Shwachman-Diamond syndrome (SBDS gene mutations) features exocrine pancreatic insufficiency, skeletal abnormalities, and neutropenia progressing to AA. Other rarer syndromes include Diamond-Blackfan anemia (RPS19 and other ribosomal protein genes) and severe congenital neutropenia (ELANE, HAX1), which may evolve into AA or myelodysplasia.

Environmental risk factors extend beyond benzene and radiation. Pesticide exposure (e.g., organophosphates, carbamates) and certain herbicides (e.g., paraquat) correlate with increased AA incidence in epidemiologic studies. Smoking is associated with modestly elevated risk, possibly via oxidative metabolites and chronic inflammation. Socioeconomic factors—including lower socioeconomic status and rural residence—may reflect unmeasured environmental exposures or limited healthcare access delaying diagnosis. Age is a notable demographic risk factor: acquired AA peaks in young adults (20–25 years) and older adults (>60 years), with distinct immune profiles—youthful cases show stronger Th1/Tc1 polarization, whereas elderly patients exhibit more clonal hematopoiesis and higher rates of evolution to MDS.

Immunogenetic susceptibility plays a key role: specific HLA alleles (e.g., HLA-DR2, HLA-B14, HLA-DR15) are overrepresented in AA patients, suggesting impaired self-tolerance to hematopoietic antigens. Polymorphisms in cytokine genes (e.g., TNF-α promoter variants) and immune checkpoint regulators (e.g., CTLA-4) further modulate risk. Importantly, while many exposures are widespread, only a small fraction of exposed individuals develop AA—highlighting the necessity of individual genetic and immunologic susceptibility. Early recognition of risk factors—including unexplained cytopenias, personal/family history of marrow failure or telomere biology disorders, occupational solvent exposure, or recent hepatitis—enables timely referral to hematology for bone marrow biopsy, telomere length testing, and chromosomal breakage analysis to distinguish acquired from constitutional disease and guide therapy (e.g., immunosuppression vs. hematopoietic stem cell transplantation).

Aplastic anemia (AA) is a rare, life-threatening hematologic disorder characterized by bone marrow failure resulting in pancytopenia—profound deficiency of erythrocytes, leukocytes, and platelets—due to immune-mediated destruction or functional impairment of hematopoietic stem and progenitor cells. The clinical presentation reflects the consequences of cytopenias and evolves gradually in most cases, though rapid progression may occur in severe forms. Early symptoms are often nonspecific and insidious, leading to frequent delays in diagnosis. Patients commonly report fatigue, exertional dyspnea, and pallor—hallmarks of progressive anemia—often attributed initially to stress, viral illness, or iron deficiency. Mild, persistent headaches, lightheadedness upon standing (orthostatic intolerance), and diminished exercise tolerance may precede overt laboratory abnormalities by weeks to months. Low-grade fever without localized signs of infection may be present due to subtle neutropenia-related immune dysregulation, though overt infections are uncommon at this stage. Easy bruising or prolonged bleeding from minor cuts may be dismissed as incidental; similarly, recurrent epistaxis or menorrhagia in women may be misinterpreted as gynecologic or dermatologic issues. Petechiae—especially on the lower extremities or oral mucosa—are frequently overlooked by patients but represent early thrombocytopenic signs.

Typical symptoms emerge as cytopenias deepen and reflect the triad of bone marrow failure. Severe anemia manifests as profound fatigue, tachycardia, systolic flow murmurs, angina pectoris (particularly in patients with underlying coronary artery disease), and congestive heart failure in susceptible individuals. Neutropenia—typically absolute neutrophil count (ANC) <1.5 × 10⁹/L, and often <0.5 × 10⁹/L in severe AA—predisposes to recurrent, often indolent bacterial and fungal infections: sinusitis, gingivitis, perirectal abscesses, pneumonia (notably with *Pseudomonas aeruginosa*, *Staphylococcus aureus*, or *Aspergillus* spp.), and sepsis. Fever of unknown origin is a cardinal red flag. Thrombocytopenia (platelet count <100 × 10⁹/L, frequently <20 × 10⁹/L) causes mucocutaneous bleeding: spontaneous gingival oozing, conjunctival hemorrhages, menorrhagia, gastrointestinal bleeding (melena or hematemesis), and intracranial hemorrhage—a leading cause of early mortality. Physical examination may reveal pallor, petechiae, ecchymoses, retinal hemorrhages, and signs of active infection (e.g., pharyngeal exudates, pulmonary crackles). Splenomegaly is notably absent—its presence strongly argues against idiopathic AA and suggests alternative diagnoses such as myelodysplastic syndrome (MDS), large granular lymphocyte leukemia, or infiltrative disorders.

Accompanying symptoms include low-grade constitutional features: night sweats, weight loss (>5% body weight over 6 months), and malaise. Some patients report mild arthralgias or myalgias, possibly reflecting underlying immune activation. Rarely, autoimmune phenomena co-occur—such as vitiligo, thyroiditis, or paroxysmal nocturnal hemoglobinuria (PNH) clone expansion (detected in ~50% of AA patients via flow cytometry)—which may manifest as dark urine (hemoglobinuria), dysphagia (achalasia), or thrombosis (abdominal vein thrombosis). However, classic PNH symptoms are uncommon in isolated AA; their emergence warrants re-evaluation for evolving PNH or AA-PNH syndrome.

Complications arise directly from cytopenias or treatment-related factors. Hemorrhagic complications include life-threatening intracranial, pulmonary, or gastrointestinal hemorrhage. Infectious complications dominate morbidity and mortality: neutropenic sepsis, invasive fungal infections (e.g., invasive aspergillosis), and reactivation of latent viruses (e.g., CMV, EBV, HHV-6) are major concerns, especially during immunosuppressive therapy (IST) or prior to hematopoietic stem cell transplantation (HSCT). Iron overload develops in transfusion-dependent patients after ≥20 units of packed RBCs, contributing to end-organ damage (cardiac arrhythmias, hepatic fibrosis, endocrine dysfunction). Clonal evolution represents a serious late complication: 10–15% of patients develop MDS (often with monosomy 7 or del(7q)) or acute myeloid leukemia (AML) within 5–10 years, particularly following IST. Secondary malignancies—including solid tumors—may arise due to chronic immune dysregulation or alkylating agent exposure (e.g., cyclophosphamide in refractory cases). Graft-versus-host disease (GVHD) and transplant-related mortality remain significant risks post-HSCT.

Diagnosis requires integration of clinical, laboratory, and morphologic findings. Complete blood count (CBC) with peripheral blood smear is the initial test, revealing pancytopenia with normocytic, normochromic anemia, absolute neutropenia, and thrombocytopenia; the smear shows absence of dysplastic features (e.g., no hypogranular neutrophils, no Pelger-Huët anomaly, no megaloblastosis). Reticulocyte count is inappropriately low (<1% or absolute <60 × 10⁹/L), confirming inadequate marrow response. Bone marrow aspiration and biopsy—mandatory for definitive diagnosis—demonstrate markedly hypocellular marrow (<25% cellularity for age, often <10%), with replacement by fat and preserved architecture; lymphocytes, plasma cells, and mast cells may be relatively increased, but megakaryocytes are severely reduced or absent. Flow cytometry for PNH clone (CD55/CD59 on granulocytes/RBCs) and cytogenetics (karyotype ± FISH for 7q-, +8, del(20q)) are essential to exclude clonal hematopoiesis. Serum vitamin B12, folate, copper, and HIV testing rule out nutritional or infectious mimics. Parvovirus B19 PCR may be considered in suspected transient red cell aplasia.

Differential diagnosis is broad and hinges on excluding other causes of pancytopenia and marrow failure. Hypocellular MDS must be distinguished by cytogenetic abnormalities, dysplastic morphology (even if subtle), and presence of ring sideroblasts or excess blasts. Acute leukemia typically shows hypercellular marrow with blasts, though hypoplastic AML occurs rarely. Myelofibrosis may present with teardrop poikilocytes and leukoerythroblastic smear, but marrow is fibrotic—not hypocellular—and splenomegaly is prominent. Infiltrative disorders (e.g., lymphoma, metastatic carcinoma, Gaucher disease) show abnormal cells or storage material on biopsy. Nutritional deficiencies (B12/folate) cause macrocytic anemia and hypersegmented neutrophils; copper deficiency mimics AA but shows neutropenia and myeloneuropathy. Viral infections (EBV, HIV, hepatitis viruses) and drugs (chemotherapy, chloramphenicol, sulfonamides, gold, phenytoin) can induce reversible marrow suppression. Autoimmune conditions like systemic lupus erythematosus (SLE) may cause cytopenias but usually retain marrow cellularity and exhibit autoantibodies and multiorgan involvement. Finally, inherited bone marrow failure syndromes (e.g., Fanconi anemia, dyskeratosis congenita) should be considered in young patients (<40 years) with physical stigmata (e.g., skin pigmentation, nail dystrophy, short stature) or family history; telomere length testing and genetic panels are indicated.

Aplastic anemia (AA) is a rare, life-threatening bone marrow failure disorder characterized by pancytopenia—profound deficiency of red blood cells, white blood cells, and platelets—due to hypocellular or aplastic bone marrow with absent or markedly reduced hematopoietic stem and progenitor cells. The pathogenesis involves immune-mediated destruction of hematopoietic stem cells, often triggered by environmental exposures (e.g., benzene, certain drugs such as chloramphenicol or sulfonamides), viral infections (e.g., parvovirus B19, hepatitis viruses, Epstein-Barr virus), or underlying genetic predispositions (e.g., Fanconi anemia, dyskeratosis congenita). Diagnosis requires peripheral blood cytopenias in at least two lineages, bone marrow aspirate and biopsy demonstrating hypocellularity (<25% cellularity for age, or <50% with residual fat replacement), and exclusion of infiltrative, clonal, or autoimmune disorders (e.g., myelodysplastic syndromes, large granular lymphocyte leukemia, paroxysmal nocturnal hemoglobinuria). Risk stratification—based on severity (non-severe, severe, very severe)—guides therapeutic decisions.

Conservative management serves as supportive care and is essential across all disease severities. It includes rigorous infection prevention (hand hygiene, neutropenic precautions, avoidance of live vaccines), prompt empiric broad-spectrum antibiotics for febrile neutropenia (e.g., piperacillin-tazobactam ± vancomycin), antifungal prophylaxis (e.g., posaconazole or voriconazole) in high-risk patients, and transfusion support. Red blood cell transfusions are indicated for symptomatic anemia (e.g., Hb <7–8 g/dL or with fatigue, dyspnea, angina); however, chronic transfusion carries risks of iron overload, alloimmunization, and transfusion-transmitted infections. Platelet transfusions are reserved for active bleeding or platelet counts <10 × 10⁹/L (or <20 × 10⁹/L in febrile or septic patients). Iron chelation therapy (deferasirox or deferoxamine) is initiated after ≥20 units of RBCs or serum ferritin >1000 ng/mL to prevent end-organ damage. Growth factors (e.g., G-CSF) are not routinely recommended due to lack of survival benefit and theoretical risk of clonal evolution.

Pharmacologic therapy targets the underlying immune dysregulation. First-line immunosuppressive therapy (IST) for patients ineligible for allogeneic hematopoietic stem cell transplantation (allo-HSCT)—particularly those over 40 years, lacking matched sibling donors, or with comorbidities—involves horse or rabbit antithymocyte globulin (ATG) combined with cyclosporine A (CsA). Horse ATG (equine-derived) demonstrates superior response rates (~60–70% at 6 months) compared to rabbit ATG (~30–40%), though both require careful monitoring for serum sickness, infusion reactions, and nephrotoxicity. CsA is titrated to maintain trough levels of 150–250 ng/mL and continued for ≥6 months post-response, then tapered slowly over 6–12 months to minimize relapse (occurring in ~30–40% of responders). Eltrombopag, a thrombopoietin receptor agonist, has revolutionized IST: when added to standard ATG/CsA, it significantly improves hematologic response rates (up to 90% at 6 months), accelerates trilineage recovery, and reduces relapse and clonal evolution. It is FDA- and NMPA-approved for refractory or first-line AA and is dosed at 50 mg daily, escalated to 150 mg based on tolerance and response. For refractory cases, second-line options include alemtuzumab, high-dose cyclophosphamide, or combination regimens; however, these carry higher toxicity and limited evidence.

Allogeneic hematopoietic stem cell transplantation remains the only curative modality and is the preferred first-line treatment for young patients (<40 years) with a human leukocyte antigen (HLA)-matched sibling donor. Outcomes are excellent: 5-year overall survival exceeds 90%, with rapid and durable engraftment. For patients lacking a matched sibling, matched unrelated donor (MUD) transplants have improved substantially with high-resolution HLA typing and post-transplant cyclophosphamide-based graft-versus-host disease (GVHD) prophylaxis, achieving 5-year survival of 75–85%. Haploidentical transplants are increasingly viable alternatives in experienced centers, particularly in China, where innovative platforms using T-cell depletion and optimized conditioning (e.g., fludarabine/cyclophosphamide/antithymocyte globulin) yield comparable outcomes to MUD. Transplant-related mortality, GVHD, and late effects (e.g., infertility, secondary malignancies) necessitate careful patient selection and long-term follow-up.

China offers distinct advantages in AA management. First, the National Clinical Research Center for Hematology (Tianjin) and leading institutions—including Peking University People’s Hospital, Shanghai Ruijin Hospital, and West China Hospital—have established standardized, evidence-based protocols aligned with international guidelines (EBMT, ASH, Chinese Society of Hematology). Second, China pioneered large-scale real-world studies validating eltrombopag in Asian populations and contributed pivotal data to global regulatory approvals. Third, cost-effectiveness is notable: NMPA-approved biosimilar ATG and domestically manufactured eltrombopag reduce treatment costs by 40–60% versus Western counterparts, improving accessibility. Fourth, China’s robust donor registries (China Marrow Donor Program, CMDP, with >3.5 million donors) and rapid HLA typing infrastructure enable timely donor identification. Fifth, integrated traditional Chinese medicine (TCM) adjuncts—such as Bu Zhong Yi Qi Tang or Shenmai injection—are used under strict clinical trial frameworks to ameliorate fatigue and improve quality of life, though they are never substituted for definitive therapy.

Recovery and long-term follow-up are critical. Patients achieving response must undergo lifelong surveillance: complete blood counts every 1–3 months for the first 2 years, then quarterly; annual bone marrow biopsies for the first 5 years to detect clonal evolution (e.g., monosomy 7, PNH clones, MDS). Vaccination status should be updated post-IST or transplant (avoiding live vaccines for ≥24 months post-IST or until immune reconstitution). Psychosocial support, nutritional counseling (iron- and folate-rich diet; avoidance of raw seafood/meats), and fertility preservation discussions (especially pre-transplant) are integral. Patients should avoid NSAIDs, aspirin, and herbal supplements with anticoagulant properties. Pregnancy requires multidisciplinary planning due to relapse risk and fetal complications. With modern therapies, 5-year survival exceeds 85% for severe AA treated appropriately—underscoring the importance of early referral to specialized hematology centers, timely risk stratification, and individualized integration of supportive, pharmacologic, and transplant strategies.